James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Omega Healthcare Investors Inc (OHI) Is an 8% Yielder Built to Last

OHI stock has had a couple of tough years, but Omega Healthcare is healthier than it's ever been. It's time to buy while the yield is juicy.

The Future of Nvidia Stock Still Depends on This

Critiques of Nvidia have mostly focused on artificial intelligence and autonomous driving, but NVDA stock is ultimately going to be driven by its presence in the GPU market.

Rite Aid Corporation (RAD) Stock Has Hit the Worst-Case Scenario

RAD stock was pummeled on Friday amid reports that the FTC is planning to tell Walgreens it can't throw Rite Aid a much-needed lifeline.

Why NewLink Genetics Corp (NLNK), Urban Outfitters, Inc. (URBN) and Dell Technologies Inc (DVMT) Are 3 of Today’s Worst Stocks

Dell Technologies (DVMT), NewLink Genetics (NLNK) and Urban Outfitters (URBN) shareholders couldn't wait for Thursday's action to come to a close.

Why Bank of America Corp (BAC) Stock Will Reward Your Patience

Bank of America has struggled since March, but that's OK. BAC stock is laying a much, much longer-term foundation than that.